Fiduciary Trust Co increased its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 56.2% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,223 shares of the company's stock after buying an additional 4,039 shares during the period. Fiduciary Trust Co's holdings in AstraZeneca were worth $735,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in AZN. Banque Transatlantique SA purchased a new stake in AstraZeneca during the fourth quarter valued at about $26,000. Albion Financial Group UT raised its position in AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company's stock valued at $40,000 after purchasing an additional 248 shares in the last quarter. CoreCap Advisors LLC raised its position in AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company's stock valued at $42,000 after purchasing an additional 155 shares in the last quarter. Crews Bank & Trust purchased a new stake in AstraZeneca during the fourth quarter valued at about $55,000. Finally, Golden State Wealth Management LLC purchased a new stake in AstraZeneca during the fourth quarter valued at about $55,000. Hedge funds and other institutional investors own 20.35% of the company's stock.
AstraZeneca Stock Up 0.4%
Shares of NASDAQ:AZN opened at $67.57 on Monday. The stock's 50-day moving average price is $71.33 and its 200-day moving average price is $69.65. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $87.68. The stock has a market capitalization of $209.55 billion, a P/E ratio of 29.90, a price-to-earnings-growth ratio of 1.42 and a beta of 0.40. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. AstraZeneca's quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the firm earned $2.06 earnings per share. On average, equities analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms have weighed in on AZN. BNP Paribas began coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price target on the stock. Morgan Stanley initiated coverage on AstraZeneca in a research note on Wednesday, February 12th. They set an "overweight" rating on the stock. Finally, UBS Group raised AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca presently has a consensus rating of "Buy" and an average price target of $88.00.
Get Our Latest Report on AZN
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
